Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of IM on the Molecular Response in Patients With LMC in Chronic Phase Treated With IM 400 mg / Day for at Least Two Years, Complete Cytogenetic Response for at Least One Year
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms MIM
- 30 Dec 2020 Number of treatment arms has been increased from 1 to 3 and the trial design has been changed from single group assignment to parallel assignment. Imatinib 600 and Imatinib 400 have been added to the randomized part of the treatment and another imatinib has been labelled as the parallel arm of the trial.
- 26 Apr 2013 New trial record